BIG FLATS, NY--(Marketwire - December 22, 2008) - X-GEN Pharmaceuticals announced that it will begin marketing Acetazolamide for Injection USP. The product is AP rated and equivalent to Diamox®(1) by Duramed Pharmaceuticals. Acetazolamide for Injection USP is indicated for adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.
Acetazolamide for Injection USP is supplied as a sterile, preservative-free lyophilized powder. Each vial contains acetazolamide sodium equivalent to 500mg of acetazolamide. It is packaged in single vial cartons NDC# 39822-0190-1, and should be stored at 20° - 25° C (68° - 77° F) [See USP Controlled Room Temperature].
X-GEN President and CEO Susan Badia points out that the introduction of Acetazolamide for Injection USP is another demonstration of X-GEN's commitment to reliable and affordable patient care. "Currently there is only one supplier of Acetazolamide for Injection USP. Our launch of this product will ensure consistent supply and steady, competitive price levels. We look forward to serving the healthcare community as the preferred source for Acetazolamide for Injection USP."
About X-GEN
X-GEN Pharmaceuticals, Inc. is focused on the development, manufacture and delivery of specialty pharmaceutical products which serve the healthcare community as effective, generic treatment choices. X-GEN's expanding product line offers a broad range of dosage forms including injectables, anti-infective solutions, oral solids, and inhalants. For further information about X-GEN Pharmaceuticals, call (866) 390-4411, or visit the web-site at www.x-gen.us.
(1) Diamox® is a registered trademark of Duramed Pharmaceuticals.